We claim:

1. Use of an effective dose of masupirdine, or a pharmaceutically acceptable salt thereof in combination with an acetylcholinesterase inhibitor or NMDA receptor antagonist, in the manufacture of a medicament for the treatment of agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, euphoria/elation, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with dementia, wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine or a pharmaceutically acceptable salt thereof; and the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the pharmaceutically acceptable salt of masupirdine is dimesylate monohydrate.

3. The use of claim 2, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.

4. The use of claim 2 or claim 3, wherein the NMDA receptor antagonist is memantine hydrochloride.

5. The use as claimed in any one of claims 2 to 4, wherein the effective dose of masupirdine dimesylate monohydrate and donepezil hydrochloride, if present, is to be administered to the patient.

6. The use as claimed in any one of claims 2 to 4, wherein the effective dose of masupirdine dimesylate monohydrate and memantine hydrochloride, if present, is to be administered to the patient.

7. The use of any one of claims 1 to 6, wherein the dementia is selected from Alzheimer’s disease dementia, dementia associated with schizophrenia, Parkinson’s

disease dementia, Lewy body dementia, vascular dementia, or frontotemporal dementia.

8. The use of claim 1, wherein the agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with Alzheimer's disease dementia.

9. The use of claim 1, wherein the agitation/aggression, delusions, hallucinations, delusions and hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, or appetite and eating change in a patient with Parkinson's disease dementia.

10. The use of claim 1, wherein 25 mg to 125 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

11. The use of claim 1, wherein 25 mg to 75 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

12. The use of claim 1, wherein 75 mg to 125 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

13. The use of claim 1, wherein 50 mg or 100 mg of masupirdine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

14. The use of claim 1, wherein 5 mg to 25 mg of donepezil or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

15. The use of claim 1, wherein 5 mg to 30 mg of memantine or a pharmaceutically acceptable salt thereof is to be administered to the patient, per day.

16. The use of claim 1, wherein the effective dose is to be administered to the patient by oral routes.

17. The use of claim 1, wherein the effective dose is to be administered to the patient by nasal routes.

18. The use of claim 1, wherein the effective dose is to be administered to the patient by local routes.

19. The use of claim 1, wherein the effective dose is to be administered to the patient by parenteral routes.

20. The use of claim 1, wherein the effective dose is to be administered to the patient one to three times per day, one to three times per week, or one to three times per month.